Skip to content

Released Nov 4, 2022, before the open

10-Q filed Nov 4, 2022, 35 days after period end · 0001764013-22-000140

Q2 2023 · 10-Q
Revenue—
Net Income-$47.93MN/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.41N/M vs Q2 2022N/M vs Q1 2023
Operating Cash Flowderived-$20,186,000N/M
Free Cash Flowderived-$20,217,000N/M

What the release said

The release

Same quarter

MetricQ2 2023Q2 2022Q2 2018
Net Income-$47.93M-$37.70M-$6.35M
EPS Diluted-$0.41-$0.35—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR